ライフサイエンスコーパス: intellectual property

1 regarding consent for future data mining and intellectual property.

2 readiness to benefit financially from their intellectual property.

3 or to resolve disputes over the ownership of intellectual property.

4 nd may place limitations on the licensing of intellectual property.

5 or to make or sell products that embody the intellectual property.

6 to reduce environmental release and protect intellectual property.

7 emia; particularly when addressing issues of intellectual property.

8 s of engineered organisms, and protection of intellectual properties.

9 ng patents that dominate embryonic stem cell intellectual property?

10 east one such dispute in the previous year), intellectual property (30 percent), and control of or ac

11 estions, including increasing concerns about intellectual property and conflict of interest.

12 ive explains how to work through the general intellectual property and contractual issues for all res

13 l report of a problem through discussions of intellectual property and sample management, study desig

14 f medical research, the process of patenting intellectual property, and its potential impact on facul

15 outlined: define policy solutions to patent, intellectual property, and liability law barriers; creat

16 a wealth of new knowledge, become topics of intellectual property, and spawned a vibrant field of ca

17 d court decisions if they are to seek useful intellectual property as a basis for technology transfer

18 e issues of regulatory approval, patents and intellectual property, assessment of value and cost-effe

19 aws constrain the use of property, including intellectual property, by a firm with market power and m

20 Notably, intellectual property can be protected prior to publicat

21 s, publication and protection from premature intellectual property claims.

22 ngly challenging for both the scientific and intellectual-property communities.

23 o the vagaries and potential divisiveness of intellectual property considerations.

24 ine has decisively liberated states from the intellectual property constraints that bind private corp

25 In the intellectual property context, an obligation to make pro

26 ion is vital, for example in cases involving intellectual property disputes and in monitoring and saf

27 eric competition and aid drug companies with intellectual property extensions, tax relief and guarant

28 Academic ownership of intellectual property facilitated wide dissemination and

29 els made up of persons who have expertise in intellectual property, finance, and research, but who ar

30 onfluence of the Web and a spirit of sharing intellectual property have fueled a worldwide movement t

31 also ascertain that they have a very strong intellectual property (IP) position to weather competiti

32 ity, promoting appropriate use, and managing intellectual property issues.

33 The intellectual property laws in the United States provide

34 nts were more likely to receive funding from intellectual property licensing (27% vs 16%, P = .01).

35 It is clear that the intellectual property model challenged by the Myriad dec

36 ows scientists consider the proliferation of intellectual property protection to have a strongly nega

37 ing data publicly available sometimes raises intellectual property questions in the minds of depositi

38 individuals and institutions that developed intellectual property related to stent technology early

39 research organization and productivity, and intellectual property remain to be examined.

40 There is a need to assess intellectual property rights ("IPRs") that may impede ge

41 Advances in protection of intellectual property rights (IPR) are also applicable t

42 Within the past century, however, intellectual property rights (IPRs) have threatened this

43 res to optimally manage data, materials, and intellectual property rights (IPRs).

44 tion's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum

45 Protection of intellectual property rights encourages private sector i

46 The intellectual property rights for some genes can become h

47 Because all intellectual property rights have been provided free of

48 However, the recent proliferation of intellectual property rights in biomedical research sugg

49 Controversy over intellectual property rights in the results of large-sca

50 chnology research cites ethical, safety, and intellectual property rights issues.

51 Otherwise, more intellectual property rights may lead paradoxically to f

52 t are important to them, namely, production, intellectual property rights, and product liability, mus

53 f patients, and attitudes to the eschewal of intellectual property rights.

54 confidential, protected by regulations about intellectual property rights.

55 erty, substantially increasing and expanding intellectual-property rights, and generated clear gains

56 rea, the proximity of processing facilities, intellectual property, safety and economics.

57 obal minimum standards for the protection of intellectual property, substantially increasing and expa

58 An analysis of recent trends in intellectual property that impact early- to mid-stage li

59 addressed the distribution of royalties from intellectual property, the future use of archival sample

60 f publication, authorship, data-sharing, and intellectual property vary considerably.

61 lerating enzyme discovery and development of intellectual property will also be highlighted.

62 s in the United States provide the owners of intellectual property with discretion to license the rig